

WHO Technical Report Series

1009

# WHO Expert Committee on Drug Dependence

---

Thirty-ninth report



World Health  
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 80.00 (CHF 105.00/US\$ 126.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int); order online: <http://www.who.int/bookorders>).

W H O T e c h n i c a l R e p o r t S e r i e s  
1 0 0 9

# WHO Expert Committee on Drug Dependence

---

Thirty-ninth report

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization



**World Health  
Organization**

WHO Expert Committee on Drug Dependence: Thirty-ninth report

(WHO Technical Report Series, No. 1009)

ISBN 978-92-4-121018-8

ISSN 0512-3054

©World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** WHO Expert Committee on Drug Dependence, thirty-ninth report. Geneva: World Health Organization; 2018 (WHO Technical Report Series, No. 1009). Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Layout L'IV Com Sàrl, Villars-sous-Yens, Switzerland.  
Printed in France.

# Contents

<b>WHO Expert Committee on Drug Dependence</b>	<b>v</b>
<b>General terms</b>	<b>vii</b>
<b>Chemical names</b>	<b>viii</b>
<b>Introduction</b>	<b>1</b>
<b>Declarations of interest</b>	<b>3</b>
<b>1. Briefings from international organizations on their work on the public health element of the world drug problem</b>	<b>4</b>
1.1 Update from the International Narcotics Control Board	4
1.2 Update from the United Nations Office on Drugs and Crime	5
1.3 Update from the Department of Essential Medicines and Health Products (WHO)	6
1.4 Update from the Department of Mental Health and Substance Abuse (WHO)	8
1.5 Update from the Department of HIV/AIDS	9
<b>2. Update from the second Informal Working Group of the ECDD</b>	<b>10</b>
<b>3. Follow-up on recommendations made by the ECDD at its thirty-eighth meeting</b>	<b>12</b>
3.1 U-47700	12
3.2 Butyrfentanyl	12
3.3 4-MEC	12
3.4 Ethylone	12
3.5 Pentedrone	13
3.6 Ethylphenidate	13
3.7 Methiopropamine (MPA)	13
3.8 MDMB-CHMICA	13
3.9 5F-APINACA	13
3.10 XLR-11	13
<b>4. Proposed WHO surveillance system for new psychoactive substances (NPS)</b>	<b>14</b>
<b>5. Review of psychoactive substances</b>	<b>15</b>
5.1 AB-CHMINACA	15
5.2 5F-ADB/5F-MDMB-PINACA	17
5.3 4-Fluoroamphetamine (4-FA)	19
5.4 AB-PINACA	21
5.5 Ocfentanil	23
5.6 Furanyl fentanyl	24
5.7 Acryloylfentanyl (Acrylfentanyl)	26
5.8 Carfentanil	27

5.9	4-Fluoroisobutyrfentanyl (4-FIBF, pFIBF)	30
5.10	Tetrahydrofuranyl fentanyl (THF-F)	32
5.11	UR-144	33
5.12	5F-PB-22	35
5.13	Etizolam (INN)	37
5.14	Pregabalin	39
5.15	Cannabidiol (CBD)	41
5.16	Tramadol	43
<b>6.</b>	<b>Cannabis pre-reviews: update on progress of planned reviews for 2018</b>	<b>46</b>
<b>7.</b>	<b>Other priorities for the ECDD</b>	<b>47</b>
7.1	Exemptions related to opioids in Schedule 3 of the 1961 Convention	47
7.2	Global opioid crisis: role of the ECDD	47
7.3	Future agenda items	47
	<b>Acknowledgements</b>	<b>48</b>
	<b>References</b>	<b>48</b>

# WHO Expert Committee on Drug Dependence

Geneva, Switzerland, 6–10 November 2017

## Members

Professor Patrick M. Beardsley, Professor of Pharmacology and Toxicology, Institute for Drug and Alcohol Studies, & Centre for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, United States of America (*Rapporteur*)

Professor Bruna Brands, Senior Science Advisor, Office of Drug Science and Surveillance, Controlled Substances Directorate, Health Canada, Ottawa, Ontario, Canada (*Chair*)

Dr Ifeoma Toyin Ekwere, Senior Consultant Anaesthesiologist, Department of Anaesthesiology, University of Benin Teaching Hospital, Benin City, Nigeria

Dr Simon Elliott, Consultant Forensic Toxicologist and Managing Director of Alere Forensics, Worcestershire, England

Professor Raka Jain, Professor of Chemistry, National Drug Dependence Treatment Centre, Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India

Dr Pamela Kaduri, Addiction Psychiatrist, Department of Psychiatry and Mental Health, Muhimbili National Hospital, United Republic of Tanzania

Dr Afarin Rahimi-Movaghar, Professor of Psychiatry, Director of Iranian National Centre for Addiction Studies, Tehran University of Medical Sciences, Islamic Republic of Iran

Professor Jason White, Professor of Pharmacology and Head, School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Australia (*Co-Chair*)

## Representatives of other organizations

*International Narcotics Control Board (INCB)*

Ms Beate Hammond, Drug Control and Crime Prevention Officer, Secretariat of the INCB, Vienna, Austria

Professor Sevil Atasoy, Member of the INCB, Vienna, Austria

*United Nations Office of Drugs and Crime (UNODC)*

Mr Justice Tettey, Chief, Laboratory and Scientific Section, Research and Trend Analysis Branch, Division for Policy Analysis and Public Affairs, UNODC, Vienna, Austria

## Expert Committee on Drug Dependence Secretariat

Ms Alma Alic, Ethics Officer, Office of Compliance, Risk Management and Ethics, WHO, Geneva, Switzerland

Dr Andrew Ball, Senior Adviser on Strategy, Policy and Equity, Department of HIV/AIDS, WHO, Geneva, Switzerland

Dr Hye-Jin Cha, Scientific Officer, Pharmacology Research Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Chungcheongbuk-do, Republic of Korea (*Temporary Adviser*)

Professor Sandra Comer, Professor of Neurobiology, Department of Psychiatry, Division of Substance Use Disorders, Columbia University, New York, NY, United States of America (*Temporary Adviser*)

Dr Gilles B. Forte, Coordinator, Policy, Governance and Knowledge Management, Department of Essential Medicines and Health Products, WHO, Geneva, Switzerland (*Secretary*)

Professor Katia Gysling, Professor at the Faculty of Biological Sciences, Center for Addiction Studies, Pontificia Universidad Catolica de Chile, Santiago, Republic of Chile (*Temporary Adviser*)

Dr Suzanne Hill, Director, Department of Essential Medicines and Health Products, WHO, Geneva, Switzerland

Ms Dilkushi Poovendran, Technical Officer, Department of Essential Medicines and Health Products, WHO, Geneva, Switzerland

Dr Vladimir B. Poznyak, Coordinator, Department of Mental Health and Substance Abuse, WHO, Geneva, Switzerland

Mr Jakob Quirin, Associate Legal Officer, Office of the Legal Counsel, WHO, Geneva, Switzerland

Professor Sutisa Nudmamud-Thanoi, Associate Professor, Faculty of Medical Science, Centre of Excellence in Medical Biotechnology, Naresuan University

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_25928](https://www.yunbaogao.cn/report/index/report?reportId=5_25928)

